Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,664 across all filing types
Latest filing 2019-12-08 Capital/Financing Update
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Update to LeMaitre Vascular deal 2 pages 187.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 9th December 2019 from Admedus Limited regarding an update on a transaction with LeMaitre Vascular Inc. It details the sale of distribution rights, payment terms, milestone payments, and manufacturing agreements. The content focuses on a capital transaction and related financial terms rather than a full financial report or earnings release. The document length is 3934 characters, which is relatively short and typical for a capital/financing update announcement. There is no indication of it being an earnings release, annual report, or other report types. Therefore, the document fits best under Capital/Financing Update (CAP).
2019-12-08 English
Appendix 3B 9 pages 262.9KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules related to securities issuance and quotation. It details the issuance of new shares, terms of securities, and application for quotation on the ASX. The content is focused on the announcement of new securities issued by the company, including number, class, issue price, and purpose. There are no financial statements, management discussion, or audit information present. The document is a formal announcement of a new share issue and application for quotation rather than a full financial report or detailed investor presentation. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is sufficient and contains detailed information about the share issue, confirming it is not a mere announcement of a report but the actual issuance notice.
2019-11-25 English
Response to ASX Price and Volume Query 4 pages 721.1KB
Regulatory Filings Classification · 95% confidence The document is a formal response letter from Admedus Ltd to the ASX (Australian Securities Exchange) regarding a price query about unusual trading activity in the company's securities. The letter addresses specific questions from the ASX about whether the company is aware of any undisclosed information that could explain the trading, compliance with listing rules, and approval of the response. The content is a regulatory compliance communication rather than a financial report, earnings release, or management discussion. It does not contain financial statements, audit information, or detailed management analysis. It is also not an announcement of a report publication but a direct response to a regulatory inquiry. Therefore, this document fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2019-11-18 English
Appendix 4C - quarterly 8 pages 290.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Report for the Period to 30 September 2019' and includes detailed financial data such as cash flow statements, revenue figures, and commentary on business activities for the quarter. It references the Appendix 4C, which is a quarterly cash flow report required by the ASX Listing Rules. The content includes actual financial statements and substantive financial data for a period shorter than a full fiscal year (Q3 2019). It is not merely an announcement or a brief summary but a comprehensive quarterly financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2019
2019-10-30 English
ADAPT Carve Out Financial Statements 45 pages 875.2KB
Audit Report / Information Classification · 95% confidence The document is titled 'ADAPT® CARVE-OUT FINANCIAL STATEMENTS' and contains detailed financial statements for the ADAPT® business segment for the year ended 31 December 2018, including profit or loss, comprehensive income, financial position, changes in equity, cash flows, and extensive notes. It is a standalone financial report segment prepared for transaction and regulatory reporting purposes. The document is about 15,000 characters long, indicating it is a full report, not a brief announcement. It includes audited and unaudited financial data, detailed accounting policies, and an independent auditor's report. This matches the characteristics of an Annual Report or a standalone financial report segment. However, since it is a carve-out financial statement segment related to a transaction and not a full company annual report, and it includes an Independent Auditor's Report, it fits best under the category of Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles excluding full Annual Reports. Therefore, the correct classification is AR with high confidence. FY 2018
2019-10-30 English
CardioCel and VascuCel LeMaitre deal clarification 1
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement clarifying details about a deal involving the sale of a business segment (CardioCel and VascuCel patch business) by Admedus Limited. It provides specific financial details about the upfront payment and cash received on completion. There is no indication that this is a full financial report, audit, or earnings release. The content focuses on a transaction update related to the company's capital or financing activities. The document length is short (1516 characters), and it is not a report publication announcement or certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-10-14 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.